

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/242,700	04/19/1999	NORIKO MIZOBUCHI	20-4518P	1380
2292	7590 08/27/2002			
BIRCH STEWART KOLASCH & BIRCH			EXAMINER	
PO BOX 747 FALLS CHU	RCH, VA 22040-0747	,	GOLLAMUDI, SHARMILA S	
			ART UNIT	PAPER NUMBER
			1616	
			DATE MAILED: 08/27/2002	20

Please find below and/or attached an Office communication concerning this application or proceeding.

	· ·	Application No.	Applicant(s)			
·	,	09/242,700	MIZOBUCHI ET AL.			
	Office Action Summary	Examiner	Art Unit			
-		Sharmila S. Gollamudi	1616			
The MAILING DATE of this communication app ars on the cover sh et with th corr spond nce address						
Period for Reply						
THE - Exte after - If the - If NO - Faile - Any earn	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a reply of period for reply is specified above, the maximum statutory period we use to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be tin within the statutory minimum of thirty (30) day ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status 1)⊠	Responsive to communication(s) filed on 18 J	una 2002				
2a)⊠	· · · · · · · · · · · · · · · · · · ·	s action is non-final.				
<u> </u>	,		resocution as to the morits is			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims		,			
4)⊠ Claim(s) <u>1-6,8-10 and 14-20</u> is/are pending in the application.						
_	4a) Of the above claim(s) is/are withdrawn from consideration.					
	Claim(s) is/are allowed.					
	Claim(s) <u>1-6,8-10 and 14-20</u> is/are rejected.					
i	Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement. Application Papers						
	·					
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
•	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) D Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice of Informal f	r (PTO-413) Paper No(s) Patent Application (PTO-152)			

Art Unit: 1616

DETAILED ACTION

Amendment E received on June 18, 2002 is acknowledged.

Claims 1-6, 8-10, and 14-20 are included in the prosecution of this application.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Rejection of claim 9 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, is maintained.

Claim 9 contains the trademark/trade name Vaseline. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112, second paragraph. See *Ex parte Simpson*, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe hydrocarbon petroleum base and, accordingly, the identification/description is indefinite.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1616

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-6, 8-10, and 14-10 are rejected under 35 U.S.C. 102(b) as being anticipated by JP 3-72426.

Response to Arguments

Applicant argues that JP contains aspirin solvents and a composition containing acetylsalicylic acid, and a hydrocarbon gel is not disclosed.

Applicant's arguments have been fully considered but they are not persuasive. JP discloses aspirin and an aspirin solvent blended with an ointment base (pg. 2). JP further discloses that the ointment base may be Vaseline itself on page 5. The inclusion of an aspirin solvent does not materially effect the composition in that the aspirin or the composition functions differently. Instant specification includes water, alcohols, and surfactants in contributing to the instability of the composition but instant specification does not include an aspirin solvent other than water, contributing to instability. "A consisting essentially of claim occupies a middle ground between closed claims that are written in a 'consisting of format and fully open claims that are drafted in a 'comprising' format." If an applicant contends that additional steps or materials in the prior art are excluded by the recitation of "consisting essentially of," applicant has the burden of showing that the introduction of additional steps or components would materially change the characteristics of applicant's invention. The transitional phrase "consisting essentially of" limits the scope of a claim to the specified materials or steps

Art Unit: 1616

"and those that do not materially affect the basic and novel characteristic(s)" of the claimed invention. Note MPEP 2111.03: Transitional Phrases.

Claims 1, 2, 8-10, and 14-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Burton (4012508).

Burton discloses a topical composition of aspirin and Vaseline (Note example I in conjunction with example 10 in which Valisone is removed).

Claims 1-6 and 14-20 are rejected under 35 U.S.C. 102(b) as being anticipated by GB 2144326.

GB discloses an ointment containing acetylsalicylic acid and a hydrocarbon base of beeswax, and paraffin (Note example 1).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Art Unit: 1616

Claims 3-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Burton (4012508) in view of GB (2144326).

Burton discloses a topical composition of aspirin and Vaseline for skin disorders (Note example I in conjunction with example 10 in which Valisone is removed).

Burton does not disclose the instant amount of aspirin.

GB discloses an ointment containing acetylsalicylic acid and a hydrocarbon base of beeswax, and paraffin for dermatological disorders (Note example 1). GB discloses that that the amount of acetylsalicylic acid varies to a certain degree, however it has been found that the preferred concentration is 8-13%.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use 8-13% acetylsalicylic acid in the composition since GB notes that the concentration may be manipulated but teaches this has the preferred amount. One would be motivated to combine the teachings of Burton and GB since both references teach an acetylsalicylic acid ointment for skin disorders.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Art Unit: 1616

Page 6

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sharmila S. Gollamudi whose telephone number is 703-305-2147. The examiner can normally be reached on M-F (7:30-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees can be reached on 703-308-4628. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 709-308-0196.

SSG

August 14, 2002

JOSE'G. DEES

Kal(